CD40 Antibody (MAB89): sc-59047
- CD40 Antibody (MAB89) is a mouse monoclonal IgG1, cited in 3 publications, provided at 100 µg/ml
- raised against anti-IgM activated tonsillar B cells of human origin
- recommended for detection of CD40 of human origin by FCM
- See CD40 (H-10): sc-13128 for CD40 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for CD40 Antibody (MAB89). This work is in progress.
QUICK LINKS
SEE ALSO...
CD40 Antibody (MAB89) is a mouse monoclonal IgG1 antibody that detects CD40 in human samples through flow cytometry (FCM). CD40 is a crucial co-stimulatory molecule found on the surface of B cells, playing a vital role in the activation and proliferation of these immune cells in response to signals from activated T helper cells. The interaction between CD40 and CD40L, expressed on T cells, is essential for initiating a cascade of intracellular signaling that leads to B cell activation, immunoglobulin class switching, and the production of antibodies, including IgE. This process is particularly important for the adaptive immune response, as CD40 enables B cells to produce high-affinity antibodies tailored to specific pathogens. Furthermore, CD40 signaling is intricately linked to various post-translational modifications, such as ubiquitination, which can influence CD40 stability and activity, thereby modulating the immune response. Anti-CD40 antibody (MAB89) is an invaluable tool for researchers studying B cell activation, immune responses, and the underlying mechanisms of various immunological disorders.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD40 Antibody (MAB89) References:
- Signaling by CD40 and its mimics in B cell activation. | Bishop, GA. and Hostager, BS. 2001. Immunol Res. 24: 97-109. PMID: 11594459
- The immunobiology of CD154-CD40-TRAF interactions in atherosclerosis. | Engel, D., et al. 2009. Semin Immunol. 21: 308-12. PMID: 19616449
- Biology and clinical applications of CD40 in cancer treatment. | Fonsatti, E., et al. 2010. Semin Oncol. 37: 517-23. PMID: 21074067
- Discovery of small molecule CD40-TRAF6 inhibitors. | Zarzycka, B., et al. 2015. J Chem Inf Model. 55: 294-307. PMID: 25622654
- Metabolism-associated danger signal-induced immune response and reverse immune checkpoint-activated CD40+ monocyte differentiation. | Dai, J., et al. 2017. J Hematol Oncol. 10: 141. PMID: 28738836
- Macrophage CD40 signaling drives experimental autoimmune encephalomyelitis. | Aarts, SA., et al. 2019. J Pathol. 247: 471-480. PMID: 30471110
- CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches. | Argiriadi, MA., et al. 2019. BMC Mol Cell Biol. 20: 29. PMID: 31382872
- The Role of CD40 in Allergic Rhinitis and Airway Remodelling. | Cheng, KJ., et al. 2021. Mediators Inflamm. 2021: 6694109. PMID: 33976586
- CD40 and the effect of anti-CD40-binding on human multiple myeloma clonogenicity. | Tong, AW. and Stone, MJ. 1996. Leuk Lymphoma. 21: 1-8. PMID: 8907262
- The central role of the CD40-ligand and CD40 pathway in T-lymphocyte-mediated differentiation of B lymphocytes. | Lederman, S., et al. 1996. Curr Opin Hematol. 3: 77-86. PMID: 9372055
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD40 Antibody (MAB89) | sc-59047 | 100 µg/ml | $322.00 |